Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Review uri icon

Overview

abstract

  • In the pre-tyrosine kinase (TKI) era, allogeneic stem cell transplant (allo-SCT) was the front-line treatment of choice for young patients with chronic myelogenous leukemia (CML). Today, imatinib is well established as front-line therapy for CML, with excellent long-term outcomes. This has changed the role of allo-SCT and the number of patients undergoing allo-SCT has declined dramatically. Allo-SCT is currently recommended for patients in accelerated/blast phase disease, those who have failed a second-generation TKI and those with TKI-resistant mutations such as T315I. The role of allo-SCT in the management of CML will require continual reappraisal as medical therapies continue to evolve.

publication date

  • October 1, 2011

Research

keywords

  • Drug Resistance, Neoplasm
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Stem Cell Transplantation

Identity

PubMed Central ID

  • PMC3246008

Scopus Document Identifier

  • 80755189388

Digital Object Identifier (DOI)

  • 10.1016/j.hoc.2011.09.003

PubMed ID

  • 22054733

Additional Document Info

volume

  • 25

issue

  • 5